Evidence map›Paper›PMID 28470168›Full record

ReviewNature reviews. Disease primers2017

Anxiety disorders.

Michelle G Craske, Murray B Stein, Thalia C Eley, Mohammed R Milad, Andrew Holmes, Ronald M Rapee, Hans-Ulrich Wittchen

Erratum issued Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06853977 (Understanding the Role of Monoaminergic Neurotransmitters in Cognitive Functions Using Fast-cyclic Voltammetry in Patients With Neurological and Psychiatric Diseases Eligible for Neurosurgical Treatment), which is not on this map. Cited by 289 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
289citing papers in PubMed, 11 pooled it
42.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06853977 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

Understanding the Role of Monoaminergic Neurotransmitters in Cognitive Functions Using Fast-cyclic Voltammetry in Patients With Neurological and Psychiatric Diseases Eligible for Neurosurgical Treatment (COGAMINE)

TypeinterventionalSponsorCentre Hospitalier St AnneRan2025 to 2035Enrolled200ConditionsNeurological Diseases or Conditions, Psychiatric Diseases, Candidates for Deep Brain Stimulation, Candidates for Invasive S-EEGArmsCognitive tasks
3 · Its place in the literature

Who cites it

289 citing papers in PubMed, 11 syntheses or guidelines pooled it, 507 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Management of Anxiety in Parkinson's Disease.Movement disorders clinical practice · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Review
  19. Article
  20. Distinct Brain Drivers and Shared Cerebello-Cortical Input in ADCY5 and SGCE Hyperkinetic Movements.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article

229 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 4 countries.

Michelle G CraskeDepartment of Psychology, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095, USA.
Murray B SteinDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.
Thalia C EleyKing's College London, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK.
Mohammed R MiladDepartment of Psychiatry, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
Andrew HolmesLaboratory of Behavioral and Genomic Neuroscience, National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland, USA.
Ronald M RapeeDepartment of Psychology, Centre for Emotional Health, Macquarie University, Sydney, New South Wales, Australia.
Hans-Ulrich WittchenInstitute of Clinical Psychology and Psychotherapy, Faculty of Science, Technische Universitaet Dresden, Dresden, Germany.
Harvard University · USKing's College London · GBMacquarie University · AUNational Institute on Alcohol Abuse and Alcoholism · USTU Dresden · DEUniversity of California, Los Angeles · USUniversity of California, San Diego · US

Funding

Mouse models of stress disorders and addictionZIAAA000411 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI HOLMES, ANDREW · 2009 to 2025
$37.7M
Mouse models of the early life origins of stress disordeZ01AA000411 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI HOLMES, ANDREW · 2004 to 2008
$1.9M
Intramural NIH HHS Z01 AA000411Intramural NIH HHS Z99 AA999999Intramural NIH HHS ZIA AA000411Medical Research Council G0901874Medical Research Council G120/635Medical Research Council MR/J011762/1
6 · The paper itself

Abstract

Anxiety disorders constitute the largest group of mental disorders in most western societies and are a leading cause of disability. The essential features of anxiety disorders are excessive and enduring fear, anxiety or avoidance of perceived threats, and can also include panic attacks. Although the neurobiology of individual anxiety disorders is largely unknown, some generalizations have been identified for most disorders, such as alterations in the limbic system, dysfunction of the hypothalamic-pituitary-adrenal axis and genetic factors. In addition, general risk factors for anxiety disorders include female sex and a family history of anxiety, although disorder-specific risk factors have also been identified. The diagnostic criteria for anxiety disorders varies for the individual disorders, but are generally similar across the two most common classification systems: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and the International Classification of Diseases, Tenth Edition (ICD-10). Despite their public health significance, the vast majority of anxiety disorders remain undetected and untreated by health care systems, even in economically advanced countries. If untreated, these disorders are usually chronic with waxing and waning symptoms. Impairments associated with anxiety disorders range from limitations in role functioning to severe disabilities, such as the patient being unable to leave their home.

Indexed as

Antidepressive AgentsAnxiety DisordersCognitive Behavioral TherapyDiagnosis, DifferentialHumansQuality of LifeRisk FactorsSerotonin Plasma Membrane Transport ProteinsSex FactorsAntidepressive AgentsSerotonin Plasma Membrane Transport ProteinsSLC6A4 protein, human

Identifiers

PMID28470168
PMCPMC11009418
OpenAlexW4210615564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.